Pharmaceutical industry

The Backstop solution for the Irish border
#Association of the British Pharmaceutical Industry #European Commission #Northern Ireland #Pharmaceutical industry #UK government

Windsor Framework addresses drug supply issues in NI

The European Commission and the UK Government have reached a political agreement that they hope will address the challenges faced by citizens and businesses in Northern Ireland (NI) following Brexit. The Windsor Framework, which focuses on a variety of issues, including supply of medicines, constitutes a comprehensive set of joint… Read More

#News #Trending News

#Appointment #Big pharma #Drug discovery #Life sciences #New appointment #Pharmaceutical industry

February’s key industry appointments

There have been a number of significant appointments in the drug discovery sector over the last month. So who are the latest movers and shakers?  Amy Berrington and Montserrat Garcia-Closas, Institute of Cancer Research: Professors Amy Berrington and Montserrat Garcia-Closas have been appointed as Team Leaders at… Read More

#News

#Biopharmaceuticals #GlobalData #Market reporting #Pharmaceutical industry

Top 20 global biopharma companies report 5.4% growth

The top 20 biopharmaceutical companies have recorded a growth of 5.4% in aggregate market capitalisation – from $3.43 trillion on December 31, 2021 to $3.61 trillion on December 31, 2022.  According to analytics company GlobalData, 11 companies indicated double-digit growth, with four companies – Merck & Co (45.3%), Vertex Pharmaceuticals… Read More

#Business & Investment #Editor's Choice #Market Reports #News

#AbbVie #ABPI #Clinical trials #Eli Lilly #Life sciences #Pharmaceutical industry #Pharmaceuticals #UK #UK government

Pharma firms pull out of UK drug pricing agreement

AbbVie and Eli Lilly have left the voluntary medicines pricing agreement in protest over what they describe as “increasingly punitive revenue clawbacks”.  The companies have left the UK’s Voluntary Scheme for Branded Medicines Pricing and Access (VPAS), a long-standing agreement between government and industry with roots going back to the… Read More

#Business & Investment #News #Trending News

#AI / data analytics / healthtech / informatics #Biologics / Biotechnology #Biopharmaceuticals #Cell and gene therapy #Diversity #Market reporting #Mergers and acquisitions #Personalised medicine #Pharmaceutical industry #Precision medicine

Drug discovery in 2023: Five key predictions

As 2022 draws to a close, life sciences market analysts attempt to correctly predict what the next 12 months might bring to the drug discovery sector. DDW’s Diana Spencer summarises the key trends likely to impact the market in 2023.  1. There will be greater emphasis on diversity in clinical trials A… Read More

#Exclusive Content #Trends & Analysis

AI concept image
#AI #Drug discovery #Novel therapeutics #Pharmaceutical industry #Software

Are claims of the success of AI in drug discovery backed by science? 

Optibrium, a developer of software and artificial intelligence (AI) solutions for drug discovery, recently announced the promotion of Dr Tamsin Mansley to President of its new subsidiary to lead its US-based team and business operations. DDW’s Megan Thomas spoke with Dr Mansley to learn more about what she considers the… Read More

#Business & Investment #Exclusive Content #Opinion

#Biologics / Biotechnology #New appointment #Pharmaceutical industry #Recruitment

Who are drug discovery’s latest movers and shakers?

There have been a number of high-level career moves within the industry in the last couple of weeks. In this update, we provide a round-up of the latest senior appointments and promotions. Nick Maishman, ViroCell Biologics Nick Maishman has joined contract development and manufacturing organisation ViroCell as Chief Operating Officer. Read More

#Business & Investment #News

Lykke Hinsch Gylvin
#Boehringer Ingelheim #New appointment #Pharma #Pharmaceutical industry

Boehringer boosts pharma division with key appointment

Boehringer Ingelheim has appointed Lykke Hinsch Gylvin as Head of Medicine and Chief Medical Officer, effective November 1, 2022. Most recently, Gylvin served as Vice President, Global Medical Franchise Head, Neuroscience at Novartis. She brings more than 20 years of pharmaceutical experience, ranging from early-stage drug development to post-approval lifecycle… Read More

#Business & Investment #News

#Drug repurposing #Pharmaceutical industry

Highs and lows of drug repurposing 

Listen to this article on the DDW Podcast: DDW Editor Reece Armstrong explores the rise of drug repurposing and the benefits and disadvantages it brings to drug discovery and development.  Drug repurposing, the act of finding new clinical targets for both approved and unapproved drugs, has emerged as a viable alternative… Read More

#Business & Investment #Exclusive Content #Opinion

#Drug discovery #Pharmaceutical industry #Phenotyping #PhoreMost #Roche

PhoreMost and Roche enter drug discovery partnership

Roche and UK-based biopharmaceutical company PhoreMost have agreed to a multi-project target discovery collaboration. Under the terms of the agreement, PhoreMost will receive an upfront payment and is eligible for preclinical success-based milestones. PhoreMost will deploy its phenotypic screening platform, SITESEEKER, toward disease-relevant pathways nominated by Roche. Novel targets identified… Read More

#Business & Investment #News